

Research Article

Risk Assessment of Malignancy Index of Adenxal Masses in El-Minia University Hospital

Emad M. Ibrahim*, Momen M. Mohamed*, Hanan M. Kamel**

Ahmed R. El-Adawy* and Sameh R. Mossa*

* Department of Obstetrics & Gynaecology

** Department of Clinical Pathology,

El-Minia Faculty of Medicine

Abstract

Accurate prediction of malignancy in adnexal masses preoperatively is important for patient's counseling as well as for selecting the optimal operative approach. Several different modalities have been reported to predict malignancy in adnexal mass. These include pelvic examination, trans-abdominal and/or transvaginal ultrasonography, tumor markers as CA¹²⁵, lactate dehydrogenase and HCG levels and color Doppler. The aim of this study was to ascertain the utility of risk malignancy index in addition to power Doppler in predicting malignancy in an adnexal mass. A total of 97 women with diagnosed adnexal masses who required operative intervention were enrolled in this study in the period between September 2011 and July 2012. The women were recruited from the Gynecology Outpatient Clinic of El Minia University Hospital. All women had a preoperative the bimanual examination, measurement of the CA¹²⁵, grey scale ultrasonography and power Doppler ultrasonography and Calculation of the risk of malignancy index (RMI) was done. The final diagnosis as gold standard was based on pathological findings. Statistical analysis was done using Student t-test, correlation test and chi-square test. For all the statistical tests done the threshold of significance was (P value < 0.05). In comparing the diagnostic accuracy of US, Doppler, CA¹²⁵ and RMI in predicting malignancy in adnexal masses in this study, the RMI had the highest diagnostic accuracy and predictive values (sensitivity of 80%, specificity of 80%, PPV of 94.4% and NPP of 97.1%) compared with CA¹²⁵ (sensitivity of 70%, specificity of 80%, PPV of 93.3% and NPP of 80%), PI (sensitivity of 81%, specificity of 70%, PPV of 98.0% and NPP of 82.9%) and RI (sensitivity of 80.7%, specificity of 80%, PPV of 90.7% and NPP of 80%). We conclude on the basis of this study that RMI is the best predictor for malignancy in adnexal mass. It is simple, non-invasive and accurate. The addition of power Doppler to RMI improve the diagnostic accuracy.

Key words: Malignancy index, Adenxal masses and Risk assessment

Introduction

Adnexal mass is one of the most common indication of gynecologic intervention. They are common among women of all ages and two thirds of these masses are encountered during reproductive years.

Approximately 4-24% of adnexal masses in premenopausal women and 39-73% in postmenopausal women (Finkler et al., 1988).

Several different modalities have been reported in an attempt to predict malignancy in adnexal mass. Accurate prediction of malignancy in adnexal masses preoperatively is important for

patient's counseling as well as for selecting the optimal operative approach (laparoscopy versus laparotomy, incision type and operative procedures (cystectomy versus Oophrectomy). Several different modalities have been reported to predict malignancy in adnexal mass. These include pelvic examination, transabdominal and/or transvaginal ultrasonography, tumor markers as CA¹²⁵, lactate dehydrogenase and HCG levels and color Doppler. Recently attention have been focused on the use of power Doppler for prediction of malignancy in adnexal masses. More recently the risk of malignancy index has been investigated for prediction of malignancy in adnexal mass by

using combination of menopausal status, CA¹²⁵ levels in U/ml and a morphology index using grey scale ultrasonography.

Prediction of malignancy has been performed for many years using pelvic examination, ultrasonography, CA¹²⁵ and Doppler. Although these modalities are useful and non invasive tools for predicting malignancy in adnexal masses but cannot be used as a screening tool as it increases in many other diseases.

The aim of this study was to ascertain the utility of risk malignancy index in addition to power Doppler in predicting malignancy in an adnexal mass.

Materials and methods

A total of 50 women with diagnosed adnexal masses who required operative intervention were enrolled in this study in the period between September 2011 and July 2012. The women were recruited from the Gynecology Outpatient Clinic of El-Minia University Hospital after being approved by departmental Ethical committee. A written consent was taken from all participants after explaining the study for them.

These patients were selected, regardless the patients complaint, age and parity, all patients were recruited according to the following criteria.

Inclusion criteria:

- All patient with suspicious adnexal masses. The definition of suspicious adnexal masses in the study was those which did not met all criteria of ultrasonography for benignity and /or elevated CA¹²⁵ level (Chen et al., 2003).

The criteria of ultrasonography for benignity:

1. Size < 10 cm.
2. Unilateral.
3. Smooth border.
4. No solid parts
5. No fluid in culde sac

Patients with previous history of hysterectomy were included provided that has at least one adnexa. We exclude women who required an emergent laparotomy and those who had clinical or radiologic evidence of metastatic disease. In

addition pregnant women were also excluded from this study.

All women had a preoperative bimanual examination, measurement of CA¹²⁵, grey scale ultrasonography and power Doppler ultrasonography.

All women were subjected to the following:

1- History taking subjected age, menopausal status, residence, occupation and complain such as abdominal or pelvic pain, abdominal distension, dyspepsia, abnormal uterine bleeding, obstetric, past and family histories.

2- Pelvic examination was performed preoperatively to assess mass size, mobility (mobile, partially mobile, or fixed), mass contour (smooth or nodular), and detectable ascites. Women were considered postmenopausal if they were older than 50 years or if they had a serum FSH greater than 20 U/L.

3- CA¹²⁵ assay: CA¹²⁵ was measured using a radioimmunoassay technique (CA¹²⁵ radio-immunoassay, Abbott Laboratories, Chigaco, USA)., According to the recommendation of the manufacturer the CA¹²⁵ was considered abnormal if it is greater than 30 U/ml.

Grey scale and power Doppler ultrasonography:

Both grey scale and power Doppler ultrasonography were performed for all patients using a Toshiba 3000 A 3-5 MHz sector transducer for initial transabdominal imaging. Therefore, a 4-5 MHz transvaginal transducer was used for grey scale imaging. Information on tumor volume, suspected site of the mass, laterality, size of the mass, presence of septae and of papillary projectors, percentage of the solid component, overall echogenicity of the mass, presence of fluid in the Douglas pouch, presence of ascites and presence of metastases. papillary projection was defined as a solid tissue proliferated arising from the internal cyst wall with a height of 3 mm or greater. Masses were classified as solid if solid tissue constitute at least 80 % of the tumor and cystic if the solid tissue constitute less than 80 % of the tumor. If any solid component was noted within the cystic lesion, the percentage of the solid tissue was calculated. The largest diameters of the solid component were measured in 3 perpendicular planes, and the volume of the solid component was calculated by the same formula applied to the tumor

volume. Subsequently, the percentage of the solid component was calculated by the formula (volume of the solid component volume of the tumor) x 100. Metastasis was defined as presence of high- vascularity heterogeneous masses other than the primary tumor in the abdominal or pelvic cavity.

Doppler ultrasonarography:

After gray scale evaluation was completed, power Doppler sonography was performed on these masses. Doppler was performed on intratumoral vessels if present. If intratumoral vessels were not visualized, spectral Doppler readings were obtained from peripheral vessels. Pulsatility index (PI) and resistance index (RI)

values were calculated. the lowest values were used when a reproducible of series of waveforms were obtained. A PI less than 1.0 or RI less than or equal to 0.5 was considered suspicious. The sensitivity and specificity of various cut- off levels of PI and RI were calculated and the proper PI and RI cut- off values for differentiating the tumors were determined by receiver operator characteristics curve (ROC curve). All data were analyzed by using SPSS software version 10.0 (Chicago, USA). The student t-test was used to compare mean RI and PI between the benign and malignant group and a P value of < 0.05 was considerable to be significant.

Calculation of the risk of malignancy index (RMI)

According to Jacob et al., (1990) the RMI was calculated as follows:

$$RMI = U \text{ (ultrasound score)} \times M \text{ (menopausal score)} \times \text{serum CA-125 level (units per liter).}$$

Ultrasound findings (U): score of one point for each of the followings:

- Multilocular cysts (presence of one septum at least within the lesion).
- Presence of ascites.
- Bilateral lesions.
- Evidence of metastases.
- Evidence of solid areas.

adnexal masses were divided into 2 groups as benign and malignant adnexal masses.

Statistics:

Statistical analysis was done using Student t- test, correlation test and chi- square test. For all the statistical tests done the threshold of significance was (P value < 0.05).

Ultrasound scores:

U= 0 (absence of any US finding)

U= 1 (presence of one US finding)

The final diagnosis as gold standard was based on pathological findings. Laparotomy was done for surgical management with peritoneal washing omentectomy and lymph node biopsy. The pathological diagnosis of borderline tumor was classified as malignancy. Therefore all of

Results

Of the 52 women included in this study, 36 were premenopausal and 16 were postmenopausal. (70%) of the premenopausal women and (50%) of the post-menopausal women had a malignant tumor as shown in table (1). The histopathological diagnosis of adnexal masses is shown in table (2)

Table (1): The clinical characteristic of all patients

Patient characteristics	Benign (n= 42)	Malignant (n= 10)	P value
1- age: mean ±SD range	37.19 ± 10.74 (9-60)	48.80 ± 7.30 (40-60)	0.002*
2- parity: mean ± SD	3.71 ± 3.20	1.40 ± 2.07	0.030*
3- Menopausal status: premenopausal N. (%) Postmenopasal N. (%)	30 (71.43%) 12 (28.57%)	6 (60%) 4 (40%)	0.482
4- Body Mass Index: Mean ± SD Range	20.11 ± 4.80 (10.67-33.20)	24.77 ± 8.92 (19.03- 44.92)	0.008*

◦- presence of pain: N· (%)	36(80.7%)	10(100%)	0.446
-----------------------------	-----------	----------	-------

This table shows the clinical characteristics of all patients and that there was statistically difference between benign and malignant masses as regarding age, parity and BMI in spite

of increased incidence of malignancy with presence of pain and in postmenopausal women with no significant differences.

Table (2): Histopathological diagnosis of adnexal masses in the studied population

Pathology	Frequency	Percent
Abscess	2	3.8%
Bilat papillary serous adenocarcinoma low grade	2	3.8%
Bilat poorly diff carcinoma	2	3.8%
Brenner's tumor	2	3.8%
Dermoid	2	3.8%
Dysgerminoma	2	3.8%
Endometrioma	4	7.7%
Fibroma	2	3.8%
Fibrothecoma	4	7.7%
Haemorrhagic cyst	2	3.8%
Mucinous cystadenofibroma	4	7.7%
Mucinous cystadenoma	2	3.8%
Non Hodgkin lymphoma of colon	2	3.8%
Papillary serous cystadenoma	2	3.8%
Poorly diff. carcinoma with omental metastasis	2	3.8%
Serous cyst	2	3.8%
Serous cystadenofibroma	4	7.7%
Simple haemorrhagic cyst	2	3.8%
Simple serous adenofibroma	4	7.7%
TB lesions	4	7.7%
Total	52	100.0%

Correlation of the ultrasonographic findings with the pathological findings.

Table (3): The ultrasonographic parameters in relation to histopathology of masses.

US parameter	Benign (n=42)	Malignant (n=10)	P value
1- Tumor volume: Mean±SD Rang	311.71±188.29 (70-688)	773.70±117.14 (571-890)	<0.001*
2- Bilaterality of masses : N·(%)	2(4.8%)	4(40%)	0.002*
3- Echogenicity of masses			0.034*
Cystic : N·(%)	14(33.3%)	0(0%)	
Solid : N·(%)	10(23.8%)	7(70%)	
Mixed : N·(%)	18(42.9%)	3(30%)	
4- Presence of separate : N· (%)	18(42.9%)	7(70%)	0.328
5- Presence of ascites :N· (%)	10(23.8%)	8(80%)	0.001*
6- Presence of metastasis: N· (%)	2(4.8%)	7(70%)	<0.001*

This table shows that there is statistical difference between benign and malignant masses as regarding US parameters (tumor volume, bilaterality, echogenicity of masses,

presence of ascities and metastasis). But there was no significant difference regarding presence of septae.

Table (4): Shows US score of benign and malignant masses.

US score	Benign (n=42)	Malignant (n=10)	P value
Score (0)	6	0	0.031*
Score (1)	18	2	
Score (2)	18	8	

This table shows that there is statistical difference between benign and malignant masses as regarding US score. (P value of 0.031)

Correlation of Doppler application with the pathological findings:

Table (5): Doppler parameters in relation to histopathology of masses

Doppler parameter	Benign (n=42)	Malignant (n=10)	P value
1- Blood flow:			0.04*
Peripheral N. (%)	30 (71.4%)	2 (20%)	
Central N. (%)	6 (14.3%)	2 (20%)	
Mixed N. (%)	6 (14.3%)	6 (60%)	
2- Pulsatility Index (PI)			0.008*
Mean±SD	1.69±0.60	1.23±0.39	
Range	(0.73-2.9)	(.9-1.9)	
3- Resistance Index (RI)			0.004*
Mean±SD	0.81±0.17	0.74±0.10	
Range	(0.43-1.2)	(0.02-0.77)	

This table shows that the presence of central or mixed blood flow was found more with malignant masses than that with benign ones. The difference is statistically significant (p

value of 0.004). Also, there is statistical difference between benign and malignant masses as regarding PI and RI (p value of 0.008 and 0.004 respectively).

Correlation of serum CA125 level with the pathological findings:

Table (6): Serum CA125 level in relation to pathology

	Tumor state	Mean	SD	Range	P value
CA125	Benign	92.33	211.79	7.4-740	0.004*
	Malignant	436.30	092.61	22-1037	

This table shows that there is significant difference between benign and malignant

masses as regarding serum CA125 level (p value of 0.004)

Table (7): Diagnostic indices of CA125 at cut- off value of 30 u/ ml in differentiation between benign and malignant masses.

	Cut off	Sensitivity	Specificity	PPV	NPV
CA125	30	70%	80%	93.3%	40%

This table shows the accuracy of CA125 serum level in differentiation between benign and

malignant masses using cut- off value of 30 u/ml.

Calculation of risk of malignancy index (RMI) and its relation to the pathology:

Table (٨): Risk of Malignancy index (RMI) in relation to pathology

	Tumor state	Mean	SD	Rang	P value
RMI	Benign	٢٧٥.٥٤	٦٤٢.٦٤	٠-٢٢٣٥	٠.٠٣٢*
	Malignant	١٧٥٦.١٠	١٤٨٢.٩٠	٢٢-٤٦١١	

This table shows that there is significant difference between benign and malignant masses as regarding Risk of Malignant Index (RMI) " p value of ٠.٠٣٢".

Table (٩): Diagnostic indices of RMI at cut – off value of ٢٦٥ in differentiation between benign and malignant masses.

	Cut off	Sensitivity	Specificity	PPV	NPV
RMI	٢٦٥	٨٥%	٨٠%	٩٤.٤%	٥٧.١%

This table shows the accuracy of RMI in differentiation between benign and malignant masses using cut- off value of ٢٦٥.

Table (١٠): Diagnostic indices of Doppler in differentiation between benign and malignant masses

Index (cut- off value)	Sensitivity	Specificity	PPV	NPP
PI < ١.٢٤	٨١%	٦٠%	٨٩.٥%	٤٢.٩%
RI < ٠.٦٤	٨٥.٧١%	٤٠%	٨٥.٧%	٤٠%

This table shows the accuracy of Doppler indices (PI and RI) in differentiation between benign and malignant masses using cut-off value of ١.٢٤ and ٠.٦٤ for PI and RI respectively.

Table (١١): Diagnosis indices of CA ١٢٥, RMI and Doppler US in differentiation between benign and malignant masses

Variable	Sensitivity	Specificity	PPV	NPP
CA ١٢٥ > ٣٥	٧٠%	٨٠%	٩٣.٣%	٤٠%
RMI > ٢٦٥	٨٥%	٨٠%	٩٤.٤%	٥٧.١%
PI < ١.٢٤	٨١%	٦٠%	٨٩.٥%	٤٢.٩%
RI < ٠.٦٤	٨٥.٧١%	٤٠%	٨٥.٧%	٤٠%

This shows the accuracy of CA ١٢٥, RMI , PI and RI in differentiation between benign and malignant masses at their cut-off values.

Discussion

Ovarian cancer is the most important differential diagnosis of complex adnexal masses, so should be excluded as early as possible. It is predominantly a disease of postmenopausal women and the incidence increases with age. (Danilovich et al., ٢٠٠١).

Malignant ovarian tumors are diagnosed at an advanced stage in ٧٥% of cases and are associated with the highest mortality figures of all gynecological cancers (Jemal et al., ٢٠٠٧).

It may be difficult to determine preoperatively the nature (benign or malignant) of adnexal tumors, However, an accurate diagnosis is essential to provide optimal treatment. (Vergote et al., ٢٠٠١).

Good preoperative discrimination between benign and malignant ovarian tumors results in more women being appropriately referred for gynecologic oncology care and more women

with benign conditions undergoing conservative surgical treatment (Yazbek et al., 2008). In practice, most physicians used a combination of pelvic examination tumor markers assessment, gray scale US and Doppler characteristics to make a preoperative diagnosis of cancer especially to identify early stage ovarian cancer. Several studies have evaluated the ability of combination of different modalities to predict pelvic malignancy. However, non of these methods has gained widespread acceptance Recently, attention has been focused on the use of RMI in differentiating benign from malignant masses.

The aim of this study was to evaluate the use of risk malignancy index in combination with power Doppler in predicting malignancy in adnexal masses. In the present study, 90.9% of the masses were found to be benign and 9.1% of them were malignant. The incidence changes to be 8.8% for benign masses and 19.2% for malignant ones due to bilaterality. The most common benign tumors are haemorrhagic cyst, fibroma, cystadenofibroma and T.B. lesions and most common malignant tumors is adenocarcinomas.

In this study, the mean age of benign cases was 37 ranging from 9 years to 60 years and that of malignant cases was 49 years ranging from 40 years to 60 years. Age alone was sensitive for predicting malignancy according to the results of this study, having a significant difference (p value of 0.002). These results coincided with those to Dotlic et al., (2011) who found that the mean age of patients with benign lesions was 38 and for those with malignant masses was 51.0 years with " P value of 0.001"

In the present study, the mean value of parity have a significant difference (p value of 0.030) in relation to pathology, thus, the incidence of malignancy increased in low parity. This disagree with Yoruk et al., (2008) who found that the incidence of malignancy increased in high parity.

The main symptoms of all women were as follow pelvic pain in 88.0%, abdominal enlargement in 9.0% and lastly abdominal uterine bleeding in 4.8%. These figures correspond well with that of Dotlic et al., (2011)

As regard to the BMI we found that the mean body mass index of patients with benign tumors was 20.11 ± 2.80 and that of malignant ones was 24.77 ± 4.92 with significant difference (P value=0.008) in relation to pathology. Thus BMI values are significantly higher in patients with malignant tumors than benign ones. This coincides with Dotlic et al., (2011) and Yorul et al., (2008).

Postmenopausal women were 16 patients accounted for about 30.77% of patients in the present study, and the incidence of malignancy in these postmenopausal women was found to be 20% and premenopausal women were 36 patients accounted for 69.23% and coincidence of malignancy in this group was 20%. Thus incidence of malignancy increases in postmenopausal women with non-significant difference (P value of 0.482).

According to various studies, most ovarian tumors 80% to 85% are benign and two thirds of these occur in women in reproductive years. Approximately 4-24% of adnexal masses in premenopausal women and 39-73% in postmenopausal women were malignant. (vasilev et al., 1988)

The ultrasound score alone as a predictive value for malignancy in masses of the studied population has a significant difference (P value of 0.031) in correlation to pathology. In this study, the mean tumor volume of patients with benign masses was 311.71 ± 188.29 and that of malignant ones was 773.60 ± 116.13 with highly significant difference (P value < 0.001). This indicate malignancy increases with increased tumor volume. Also, most of malignant tumors are bilateral (60%) while 4.8% of benign tumors are bilateral with significant difference (P value of 0.002).

It was noted in this study that 100% of malignant tumors have solid or mixed echogenicity while 76.7% of benign ones have this with significant difference (P value of 0.034), thus increased solid parts of the tumor increases incidence of malignancy. This coincidence with Yoruk et al., (2008).

Presence of septae (multilocularity) is an U/S feature suspicious of malignancy. In the present study 42.9% of benign tumors have septae while

70% of malignant ones have this with no significant difference (p value of 0.328).

Also the presence of ascites and metastasis are U/S features suspicious of malignancy in the present study. Ascites and metastases present in 80% and 70% of malignant tumor respectively while present in 23.8% and 4.8% of benign tumor respectively with highly significant difference (p value of 0.001 and < 0.001 respectively) this coincides with Yoruk et al., (2008) with "P value of 0.05 and 0.000" respectively. Folkman et al., (1971) first described the importance of angiogenesis for tumor growth. In our work, we support the hypothesis that ultrasonographic evaluation of tumor angiogenesis might help to improve differentiation between benign and malignant ovarian tumors detected in screening trials, as reported by Carmeliet et al., (2000).

As regards the use of power Doppler in differentiating benign from malignant masses the mean RI and PI were 0.81 and 1.79 respectively for patient with benign masses and that for those with malignant masses were 0.74 and 1.24 respectively. The difference was statistically significant (P < 0.05).

At cut-off values of "0.74" and "1.24" values for RI and PI respectively the diagnostic accuracy of Doppler shows a sensitivity of 80.71%, 81%, specificity of 40%, 70%, positive predictive value of 80.7%, 89.0% and negative predictive value of 40%, 42.9%, respectively. This coincides with Neeyalavira et al., (2008) using cut-off PI value of 1.24, giving the sensitivity and specificity of 90.1% and 88.3%, respectively and RI value of 0.74 as the cut-off point, the sensitivity and specificity were 90.1% and 90.3% respectively. Sengoku et al., (1994) reported sensitivity and specificity of 81.3 and 91.7% respectively when the cut-off value of PI was 1.0. Timor-Tritsch et al., (1993) reported the RI value of 0.8 had sensitivity 93.8% and specificity of 98.7% which was different from the study of Zanetta et al., (1994) (RI 0.56). Maly et al., (1990), revealed a cut-off value of 0.7 for RI with a sensitivity of (77%), specificity of (53%), PPV of (22%) and NPV of (87%). Ebrashy and Ezzat (2000), found RI of 0.80 to be of 86% sensitivity while Marret et al., (2002), reported a cut-off value of 0.53 for RI with a specificity of 93%.

In general, both indices tended to be lower in malignant masses than in benign masses (Flesicher et al., 1993 and Brown et al., 1994). Although there are different opinions about cut-off values, all authors agree that recognition of angiogenesis as a reference point for malignant changes within the ovary has proved to be a highly sensitive parameter. Given that neovascularization is an obligate event in malignant change, this recognition may enable us to observe the earliest stages in ovarian oncogenesis. Neeyalavira V et al., (2008) and Guerriero et al., (2001), concluded that at least one of the two Doppler techniques, pulsed wave Doppler should be used in conjunction with gray scale imaging in order to decrease the false positive rate of gray scale imaging when used alone.

In this study, with Doppler examinations the presence of central or mixed blood flow was greater in malignant lesions (80%) than benign lesions (28.6%) and this difference was statistically significant (P < 0.004). This coincides with Yoruk et al., (2008). In the present study the mean CA125 serum level was 92.33 u/ml for the women with benign masses and 426.30 u/ml for those with malignant masses. The difference was statistically significant (P value of 0.004). At a cut-off value of 30 u/ml, CA125 had a sensitivity of 70%, a specificity of 80%, a positive predictive value of 93.3% and a negative predictive value of 40%. These figures coincide well with that of Timmerman et al., (1999) who reported that CA125 had a sensitivity of 71% for stage one primary ovarian cancer, 94% for all other primary invasive ovarian cancer, 77% for metastatic ovarian cancer and 70% for borderline malignant ovarian tumors.

In the present study, Risk of malignancy index was calculated for each patient in the studied population. The mean value for benign tumors was 270.04 ranging from 0 to 2230 and for malignant one was 1706.1 ranging from 22 to 4611. At a cut-off value > 200 or 260 provides sensitivity of 80%, specificity of 80%, positive predictive value of 94.4% and negative predictive value of 57.1% for both values with significant difference (P value of 0.032). The presence of gap between two cut-off values (200, 260) with the same accuracy could be explained by the small sample size of the

studied population, presence of gap in the levels of serum CA125 and unilaterality of most masses (88.5% of the cases, with low US score).

This results coincides well with that reported by Jacob et al., (1990) at a cut-off point of 200 to have a sensitivity of 73% and a specificity of 91% (for a RMI based on CA125, ultrasound and menopausal status). Similarly, Tingulstad et al., (1996 and 1999) found a sensitivity of 71% and specificity of 96%. In a later study in 1999 Tingulstad et al., reported a sensitivity of 71% and a specificity of 92% respectively. Also, Bouzari et al., (2011) found a sensitivity of 91.3%, specificity of 88%, PPV of 92% and NPV of 98.08%. In an extensive retrospective analysis, Bailey et al., (2006) confirmed the effectiveness of the RMI algorithm for identifying cases of ovarian malignancy presenting at cancer units for subsequent referred to a cancer.

In comparing the diagnostic accuracy of US, Doppler, CA125 and RMI in predicting malignancy in adenexal masses in this study, the RMI had the highest diagnostic accuracy and predictive values (sensitivity of 80%, specificity of 80%, PPV of 94.4% and NPP of 97.1%) compared with CA125 (sensitivity of 70%, specificity of 80%, PPV of 93.3% and NPP of 90%), PI (sensitivity of 81%, specificity of 70%, PPV of 98.0% and NPP of 92.9%) and RI (sensitivity of 80.7%, specificity of 90%, PPV of 80.7% and NPP of 90%).

Conclusion

We conclude on the basis of this study that RMI is the best predictor for malignancy in adnexal mass. It is simple, non invasive and accurate. The addition of power Doppler to RMI improve the diagnostic accuracy.

References

- 1- Bailey J, Tailor A, Naik R, Lopes A, Godfrey K, Hatem HM, Monaghan J. (2006): Risk of malignancy index for referral of ovarian cancer cases to a tertiary center: does it identify the correct cases? *Int J Gynecol Cancer*. Jan-Feb;16 Suppl 1:30-4.
- 2- Bouzari Z, Shahla Y, Ziba Sh. K., Narges A. (2011): Risk of malignancy index as an evaluation of pre-operative pelvic mass. *Caspian J. Intern. med.*, 2(4);331-335.

- 3- Brown DL, Frates MC and Laing FC (1994): Ovarian masses: Can benign and malignant lesions be differentiated with color and pulsed Doppler US? *Radiology*, 190: 333-336.
- 4- Carmeliet P, Jain RK. (2000): Angiogenesis in cancer and other diseases. *Nature*; 407:249-57.
- 5- Chen, V. W., Ruiz, B., Killeen, J. L., Coté, T. R., Wu, X. C., Correa, C. N. and Howe, H. L. (2003): Pathology and classification of ovarian tumors. *Cancer*, 97:2631-2644. doi: 10.1002/cncr.11340
- 6- Danolovich N, Roy I and Sairan MR (2001): Ovarian pathology and high incidence of sex cord tumors in follitropin receptor knock out Forko mice. *Endocrinology*, Aug, 142(8): 3773-84.
- 7- Dotlic J., Terzic M., Ivana L., Jasmina A., Nebojsa L. (2011): Evaluation of adnexal masses: correlation between clinical ultrasonography, histopathological finding. *Vojnosaint pregl*, 68(10);871-876.
- 8- Ebrashy A and Ezzat E (2000): Adding color flow Doppler measurements to the morphological scoring system in the ultrasound evaluation of adnexal masses. Does it really help? *Egy. J. Fertil. Steril*, Vol. (4)4: 48
- 9- Finkler NJ, Benacerraf B, Lavin PT, Wojlechowski C, Knapp RC (1988): Comparison of CA 125, Clinical impression, and ultrasound in the preoperative evaluation of ovarian masses: *Obstet. Gynaecol.*; 72:609.
- 10- Fleischer AC, Cullinan JA, Kepple DM and Williams LL (1993): Conventional and color Doppler transvaginal sonography of pelvic masses: A comparison of relative histologic specificities. *J. Ultrasound Med.*, 12: 705-12.
- 11- Folkman J, Merler E, Abernathy C, Williams G. (1971): Isolation of a tumor factor responsible for angiogenesis. *J Exp Med.*; 133:275-88
- 12- Guerriero S, Alcazar JL, Ajossa S.: (2001): Comparison of conventional color Doppler imaging and power Doppler imaging for the diagnosis of ovarian cancer: results of a European study. *Gynecol. Oncol.*, Nov, 82(2): 299-304.
- 13- Jacobs I, Oram D, Fiarbanks J, Turner J, Frost C and Grudzinskas JG (1990): A risk of malignancy index incorporating CA125,

- ultrasound and menopausal status for the accurate pre-operative diagnosis of ovarian cancer. *Br. J. Obstet. Gynecol.*, 97(10), 922-929.
- 14- Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. (2007): Cancer statistics, *CA Cancer J Clin*; 57: 43-76
- 15- Maly Z, Riss P and Deutinger J (1990): Localization of blood vessels and quantitative assessment of blood flow in ovarian tumors. *Obstet. Gynecol.*, 80: 33-36.
- 16- Marret H, Ecochard R, Giraudeau B.: (2002): Color Doppler energy prediction of malignancy in adnexal masses using logistic regression models. *Ultrasound Obstet. Gynecol.*, Dec; 20(6): 697-704.
- 17- Neeyalavira V., Theera T. and Channe W., (2008): Doppler indices for prediction of benign and malignant ovarian tumour. *Thai journal of obstetrics and gynecology* vol. 16, pp. 50-63.
- 18- Schutter E, Davelaar E, Kamp G. (2002): The differential diagnostic potential of a panel of tumor markers (CA125, CA19-9 and CA125-4 antigens) in patients with a pelvic mass. *Am. J. Obstet. Gynecol.*, 187: 380-392
- 19- Sengoku K, Satoh T, Saitoh S, Abe M, Ishikawa M. (1994): Evaluation of transvaginal color Doppler sonography, transvaginal sonography and CA 125 for prediction of ovarian malignancy. *Int J Gynaecol Obstet*; 86:39-43.
- 20- Timmerman D, Schwarzler P, Collins WP.: (1999): Subjective assessment of adnexal masses with the use of ultrasonography: an analysis of inter-observer variability and experience. *Ultrasound Obstet Gynecol.*; 13: 11-16
- 21- Timor-Tritsch LE, Lerner JP, Monteagudo A, Santos R. (1993): Transvaginal ultrasonographic characterization of ovarian masses by means of color flow-directed Doppler measurements and a morphologic scoring system. *Am J Obstet Gynecol*; 168: 909-13.
- 22- Tingulstad S, Hagen B, Skjel-destad FE, Halvorsen T, Nustad K, Onsrud M. (1999): The risk of malignancy index to evaluate potential ovarian cancers in local hospitals. *Br J Obstet Gynecol*; 93:448-52.
- 23- Tingulstad S, Hagen B, Skjel-destad FE, Onsrud M, Kiserud T, Halvorsen T.: (1996): Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre-operative diagnosis of pelvic masses. *Br. J. Obstet. Gynecol.*, 103(8), 826-831.
- 24- Vasilev SA, Schlaertr JB, Campeau J and Morow CP (1988): Serum CA125 levels in preoperative evaluation of pelvic masses. *Obstet. Gynecol.*, 72: 709-74.
- 25- Vergote I, De Brabanter J, Fyles A, Bertelsen K, Einhorn N, Sevelde P, Gore ME, Karn J, Verrelst H, Sjovall K, Timmerman D, Vandewalle J, Van Gramberen M, Tropé CG. *Lancet* (2001): Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma; 357: 176-182
- 26- Yazbek J, Raju SK, Ben-Nagi J.: (2008): Effect of quality of gynaecological ultrasonography on management of patients with suspected ovarian cancer: a randomized controlled trial. *Lancet Oncol.*; 9: 124-131.
- 27- Yoruk P. , Ozgur D., Begum Y., Levent T. and Tanju P. (2008): Comparison of the risk of malignancy index and self constructed logistic regression models in pre-operative evaluation of adnexal masses. *American institute of U\S in medicine*, 27:1469-1477.
- 28- Zanetta G, Vergani P, Lissoni A. (1994): Color Doppler ultrasound in the pre-operative assessment of adnexal masses. *Acta Obstet Gynecol Scand*; 73:737-41.